Previous 10 | Next 10 |
MIAMI, March 30, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today rep...
2023-03-13 08:57:19 ET First Republic FRC -64% amid woes regarding SVB, Signature collapse . Western Alliance WAL -54% amid woes regarding SVB, Signature collapse . PacWest PACW -40% amid woes regarding SVB, Signature collapse . Euda Health ( EUDA...
2023-03-09 12:48:42 ET Gainers: Intuitive Machines ( LUNR ) +74% . Ocean Biomedical ( OCEA ) +72% . Holley ( HLLY ) +55% . Build-A-Bear Workshop ( BBW ) +23% . Avenue Therapeutics ( ATXI ) +21% . Digital Brands Group ( DBGI...
2023-03-09 10:01:05 ET Gainers: Ocean Biomedical OCEA +57% . Avenue Therapeutics ( ATXI ) +21% . Unicycive Therapeutics ( UNCY ) +19% . Assertio ( ASRT ) +12% . Immuneering ( IMRX ) +11% . Losers: InVivo Therapeutics NVIV ...
2023-03-09 08:40:39 ET Ocean Biomedical ( OCEA ) +38% on sharing detailed research data on anti-tumor pathway discoveries and their potential for treatment of non-small cell lung cancer, metastatic melanoma, and glioblastoma by scientific co-founder. First Wave ( FWB...
MIAMI, March 08, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today ann...
Avenue Therapeutics ( NASDAQ: ATXI ) signed an exclusive license agreement with AnnJi Pharmaceutical to develop and sell AJ201 for treating spinal and bulbar muscular atrophy (SBMA) Under the agreement, AnnJi will get $3M upfront and is entitled to future development, regulatory ...
MIAMI, March 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today ann...
NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI). About Avenue Therapeutics, Inc. Avenue Therapeutics, Inc. (Nasdaq:ATXI) is a spe...
MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today a...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...